Medico Remedies Limited

BSE:540937 Stock Report

Market Cap: ₹4.0b

Medico Remedies Past Earnings Performance

Past criteria checks 2/6

Medico Remedies has been growing earnings at an average annual rate of 33.4%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 8.7% per year. Medico Remedies's return on equity is 13.8%, and it has net margins of 5.4%.

Key information

33.4%

Earnings growth rate

33.5%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate8.7%
Return on equity13.8%
Net Margin5.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Medico Remedies makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BSE:540937 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,41277600
30 Jun 241,44285600
31 Mar 241,44983600
31 Dec 231,31670590
30 Sep 231,40778590
30 Jun 231,38882580
31 Mar 231,40472580
31 Dec 221,44775610
30 Sep 221,36063650
30 Jun 221,25151570
31 Mar 221,21048600
31 Dec 211,19133600
30 Sep 211,19428550
30 Jun 211,20719510
31 Mar 211,22426490
31 Dec 201,14925450
30 Sep 201,07425410
30 Jun 2098020400
31 Mar 2088616390
31 Dec 1993818360
30 Sep 1999019330
30 Jun 1998417340
31 Mar 1997716340
31 Dec 1885514-130
30 Sep 1873213400
30 Jun 1867112400
31 Mar 1861012410
31 Mar 1754416450
31 Mar 16667111000
31 Mar 155108890
31 Mar 144496810

Quality Earnings: 540937 has high quality earnings.

Growing Profit Margin: 540937's current net profit margins (5.4%) are lower than last year (5.5%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 540937's earnings have grown significantly by 33.4% per year over the past 5 years.

Accelerating Growth: 540937's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 540937 had negative earnings growth (-1.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (20%).


Return on Equity

High ROE: 540937's Return on Equity (13.8%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies